

Resource Summary Report

Generated by SPARC SAWG on Aug 23, 2026

CD19

RRID:AB_2744311

Type: Antibody

Proper Citation

BD Biosciences Cat# 564655, RRID:AB_2744311

Antibody Information

URL: http://antibodyregistry.org/AB_2744311

Proper Citation: BD Biosciences Cat# 564655, RRID:AB_2744311

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: SJ25C1 (also known as SJ25-C1)

Antibody ID: AB_2744311

Vendor: BD Biosciences

Catalog Number: 564655

Alternative Catalog Numbers: 564656

Record Creation Time: 20250820T004230+0000

Record Last Update: 20250820T085914+0000

Ratings and Alerts

No rating or validation information has been found for CD19.

No alerts have been found for CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Trinh T, et al. (2023) CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. *iScience*, 26(4), 106443.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.

Burton AR, et al. (2022) The memory B cell response to influenza vaccination is impaired in older persons. *Cell reports*, 41(6), 111613.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, 183(2), 347.

Singh A, et al. (2020) Innate Lymphoid Cell Activation and Sustained Depletion in Blood and Tissue of Children Infected with HIV from Birth Despite Antiretroviral Therapy. *Cell reports*, 32(11), 108153.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. *Cell reports. Medicine*, 1(8), 100141.